MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-11-2026
Organovo Holdings EPS Ratio 2011-2026 | ONVO
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Organovo Holdings
| 2025 | 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.7 | -19.2 | -1.98 | -2.44 | -2.8 | -0.23 | -0.32 | -0.39 | -0.43 | -0.38 | -0.35 | - | -1.01 | -0.19 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.19 | -19.2 | -2.42 |
Quarterly EPS Ratio Organovo Holdings
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.03 | -0.98 | -1.14 | - | -2.28 | -1.68 | -2.74 | - | -0.4 | -0.46 | -0.46 | - | -0.37 | -0.38 | -0.37 | - | -0.4 | -1.1 | -0.69 | - | -0.37 | -0.37 | -1.36 | -0.02 | -0.6 | -0.03 | -0.05 | -0.05 | -0.06 | -0.06 | -0.05 | -0.07 | -0.07 | -0.09 | -0.1 | -0.1 | -0.09 | -0.09 | -0.1 | -0.09 | -0.11 | -0.11 | -0.12 | -0.1 | -0.09 | -0.09 | -0.11 | -0.08 | -0.07 | -0.14 | -0.21 | -0.26 | -0.2 | 0.87 | 0.07 | -1.17 | -0.01 | -0.07 | -0.01 | -0.04 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 0.87 | -2.74 | -0.37 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Diagnostics research industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-2.06 | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
-1.75 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
-0.23 | - | -6.19 % | $ 10.5 M |  USA |
 |
Accelerate Diagnostics
AXDX
|
-0.14 | - | -61.36 % | $ 2.46 M | USA |
 |
Brainsway Ltd.
BWAY
|
-0.24 | $ 23.08 | 1.7 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
-14.2 | $ 29.14 | -3.75 % | $ 326 M |  China |
 |
Biocept
BIOC
|
-1.89 | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
-88.1 | $ 1.1 | 0.46 % | $ 1.4 M | USA |
 |
Check-Cap Ltd.
CHEK
|
4.3 | - | - | $ 9.42 M | Israel |
 |
Co-Diagnostics
CODX
|
-1.2 | - | - | $ 79.8 M | USA |
 |
DarioHealth Corp.
DRIO
|
1.93 | $ 11.38 | 1.16 % | $ 323 M | Israel |
 |
DexCom
DXCM
|
2.14 | $ 70.29 | 8.0 % | $ 27.4 B | USA |
 |
Celcuity
CELC
|
-2.83 | $ 103.65 | -1.16 % | $ 4.09 B | USA |
 |
Chembio Diagnostics
CEMI
|
-0.72 | - | 0.22 % | $ 16.8 M | USA |
 |
Castle Biosciences
CSTL
|
0.66 | $ 32.89 | 3.09 % | $ 914 M | USA |
 |
Danaher Corporation
DHR
|
5.33 | $ 211.14 | -1.74 % | $ 154 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
7.78 | $ 205.13 | -0.82 % | $ 22.8 B | USA |
 |
Global Cord Blood Corporation
CO
|
4.12 | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
-0.08 | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-1.08 | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
-1.41 | $ 23.24 | 1.18 % | $ 703 M | USA |
 |
Enzo Biochem
ENZ
|
-0.51 | - | -8.98 % | $ 14.8 K | USA |
 |
CareDx, Inc
CDNA
|
-3.54 | $ 19.6 | 2.62 % | $ 1.05 B | USA |
 |
DermTech
DMTK
|
-3.09 | - | -11.32 % | $ 2.94 M | USA |
 |
Interpace Biosciences
IDXG
|
1.42 | $ 1.85 | - | $ 8.12 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-4.67 | $ 103.32 | 0.09 % | $ 19.1 B | USA |
 |
Heska Corporation
HSKA
|
-1.92 | - | - | $ 1.31 B | USA |
 |
Lantheus Holdings
LNTH
|
4.52 | $ 68.71 | -0.02 % | $ 4.75 B | USA |
 |
Guardant Health
GH
|
-3.56 | $ 104.76 | 1.95 % | $ 12.9 B | USA |
 |
QIAGEN N.V.
QGEN
|
0.38 | - | - | $ 10.6 B |  Niderland |
 |
National Research Corporation
NRC
|
1.26 | $ 12.09 | -5.81 % | $ 297 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-24.3 | - | -20.0 % | $ 1.06 M | USA |
 |
Charles River Laboratories International
CRL
|
0.2 | $ 160.2 | 0.91 % | $ 8.23 B | USA |
 |
IDEXX Laboratories
IDXX
|
10.8 | $ 627.58 | 1.68 % | $ 51.8 B | USA |
 |
Illumina
ILMN
|
-7.69 | $ 115.9 | 1.27 % | $ 18.4 B | USA |
 |
OPKO Health
OPK
|
0.02 | $ 1.24 | 2.48 % | $ 861 M | USA |
 |
IQVIA Holdings
IQV
|
7.57 | $ 166.72 | -1.27 % | $ 30.2 B | USA |
 |
Natera
NTRA
|
-5.57 | $ 204.66 | -1.53 % | $ 20.1 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
3.67 | $ 31.11 | -0.94 % | $ 20 B | Niderland |
|
Biodesix
BDSX
|
-0.33 | $ 11.55 | 6.6 % | $ 1.5 B | USA |
 |
Personalis
PSNL
|
-1.37 | $ 8.22 | -2.09 % | $ 487 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.89 | $ 281.39 | 1.13 % | $ 23.6 B | USA |
 |
ICON Public Limited Company
ICLR
|
9.6 | $ 95.34 | 19.06 % | $ 7.86 B |  Irlanda |
 |
Biomerica
BMRA
|
-2.16 | $ 2.25 | 4.19 % | $ 5.17 M | USA |
 |
Bioventus
BVS
|
-2.49 | $ 8.22 | 1.48 % | $ 515 M | USA |
 |
Medpace Holdings
MEDP
|
15.6 | $ 429.09 | 3.14 % | $ 12.4 B | USA |